drugset / Trial / NCT01751893
Testing the Effectiveness of Henna on Managing PPE
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
The palmar-plantar erythrodysesthesia (PPE) is the only clinical adverse event that commonly occurs with capecitabine and/or pegylated liposomal doxorubicin treatment and it warrants special attention because it is the most common dose-limiting toxicity. this study is designed to test the effectiveness of a henna treatment protocol in the management of capecitabine and/or pegylated liposomal doxorubicin induced palmar-plantar erythrodysesthesia.
Timeline
- Start
- 2017-06-01
- Primary completion
- 2018-05-01
- Completion
- 2018-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Henna | Unknown | 40 g | Topical |